Published: July 10, 2017 | Category:News | Spinal Cord Injury:C-4
Ability to enroll patients with second most common cervical spinal cord injury broadens eligible population for SCiStar study and future trials
FREMONT, Calif., July 10, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s amendment to the clinical research protocol for its ongoing AST-OPC1 SCiStar Phase 1/2a clinical trial in motor complete cervical spinal cord injury (SCI). The amendment expands the eligibility criteria to include patients with a C-4 spinal cord injury and extends the dosing window from 14 to 30 days to 21 to 42 days post-injury. Continue Reading »
Controversy surrounds the link between Australian of the Year Alan Mackay Sim’s research and a Polish team who restored mobility for a paraplegic man.
For many people suffering from disabling conditions, such as Parkinson’s disease, spinal injury and paralysis, multiple sclerosis, macular degeneration, heart disease, renal failure and even cancer, announcements in the press around breakthroughs in stem cell research undoubtedly bring hope.
The challenge remains how to accurately communicate what is genuinely possible in terms of therapies and what we scientists hope might be possible but do not yet have strong evidence for. Continue Reading »
Early clinical trial results announced offer new hope in regenerative medicine
A new therapy to treat spinal cord injuries in people who have lost all motor and sensory function below the injury site shows additional motor function improvement at 6-months and 9-months following treatment with 10 million AST-OPC1. The positive efficacy results from an ongoing research study were announced on Jan. 24 in a conference held by Asterias Biotherapeutics, Inc., the biotechnology company that manufactures AST-OPC1. Continue Reading »
Stem cell research is often controversial but it has also led to incredible medical progress in recent years.
Stem cell research is at defining moment. Although it can be controversial and does raise a lot of important ethical issues, this area of medical science has been characterised by a number of important advances, ever since the first embryonic stem cells were isolated from mice in the 1980s. In the near future, it could reshape the way we treat some of the world’s most debilitating diseases.
Stem cells have already been used as treatment for a number of years – think bone marrow transplant – and they have the potential to help with many other medical conditions. Continue Reading »
Chronic pain and loss of bladder control are among the most devastating consequences of spinal cord injury, rated by many patients as a higher priority for treatment than paralysis or numbness. Now a UC San Francisco team has transplanted immature human neurons into mice with spinal cord injuries, and shown that the cells successfully wire up with the damaged spinal cord to improve bladder control and reduce pain. This is a key step towards developing cell therapies for spinal cord injury in humans, say the researchers, who are currently working to develop the technique for future clinical trials. Continue Reading »
An experimental stem cell therapy developed by Asterias Biotherapeutics restored some movement to patients paralyzed by recent spinal cord injuries, according to interim data from a small study being presented on Wednesday.
One of the five patients in the trial regained use of both arms and hands, and is now able to feed himself, send texts on a phone and operate a wheelchair, the Fremont, California-based company said.
Three months after the cells were implanted, the study met its efficacy goal of two patients regaining return of two motor levels of functioning on at least one side of their body, the company said.
All five people in the study have experienced some upper extremity improvement so far, Asterias said. Continue Reading »
Initial Results Offer Hope for Patients to Reclaim Independence After Suffering Severe Spinal Injury
LOS ANGELES, Sept. 7, 2016 /PRNewswire/ — Keck Medical Center of USC today announced that a team of doctors became the first in California to inject an experimental treatment made from stem cells, AST-OPC1, into the damaged cervical spine of a recently paralyzed 21-year-old man as part of a multi-center clinical trial. Continue Reading »
Stem Cell treatment or the Human Embryonic Stem Cells (HESC) is effective in the replacement of damaged neurons, re-establishment of lost axonal connections, and providing of neuro-protective factors to allow the healing and recovery of spinal cord injury, revealed a study.
Stem Cell treatment or the Human Embryonic Stem Cells (HESC) is effective in the replacement of damaged neurons, re-establishment of lost axonal connections, and providing of neuro-protective factors to allow the healing and recovery of spinal cord injury, revealed a study. Continue Reading »
StemCells Inc., a California-based biotech company announced that they will stop developing the potential treatment for spinal cord injury after a failed mid-stage clinical trial. The company stock went down to $3.03 per share at the start of the pre-market trade. StemCells reported that they still have $5.5 million in cash as of May 31, but they don’t have a liquidating distribution to their stockholders.
The company said that the amount that they can give to the shareholders depends on the liquid assets, any liabilities, and costs of the wind down. Continue Reading »